Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients

[1]  N. Paynter,et al.  Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. , 2017, Seminars in arthritis and rheumatism.

[2]  O. Lopez,et al.  Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[3]  J. Gallacher,et al.  Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank , 2016, BMJ Open.

[4]  Paul Edison,et al.  Neuroinflammation in Alzheimer's disease: Current evidence and future directions , 2016, Alzheimer's & Dementia.

[5]  Y. Duan,et al.  Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis. , 2016, Archives of medical research.

[6]  T. Donner,et al.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. , 2015, Cytokine.

[7]  P. Chowienczyk,et al.  Are Inflammation and Related Therapy Associated with All-Cause Dementia in a Primary Care Population? , 2015, Journal of Alzheimer's disease : JAD.

[8]  Peng Li,et al.  Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis , 2015, Clinical Rheumatology.

[9]  K. Chiu,et al.  The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis. , 2015, Osteoarthritis and cartilage.

[10]  Martin Knapp,et al.  Dementia UK: Update , 2014 .

[11]  R. Klein,et al.  Long‐Term Systemic Inflammation and Cognitive Impairment in a Population‐Based Cohort , 2014, Journal of the American Geriatrics Society.

[12]  A. Simmons,et al.  Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease , 2013, PloS one.

[13]  R. Pope,et al.  Possible roles of IL-12-family cytokines in rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[14]  M. Dougados,et al.  Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement , 2012, Annals of the rheumatic diseases.

[15]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[16]  Janneke Tekstra,et al.  Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis , 2012, Annals of Internal Medicine.

[17]  T. V. van Staa,et al.  Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource , 2012, Therapeutic advances in drug safety.

[18]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[19]  P. Sachdev,et al.  The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study , 2011, AGE.

[20]  R. Fleischmann.  Don't forget traditional DMARDs. , 2011, Rheumatology.

[21]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[22]  P. Rose,et al.  Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[23]  P. Kiely,et al.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.

[24]  B. Hudson,et al.  Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. , 2009, Rheumatology.

[25]  V. Perry,et al.  Systemic inflammation and disease progression in Alzheimer disease , 2009, Neurology.

[26]  Kaleb Michaud,et al.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases , 2009, Arthritis research & therapy.

[27]  Peter C Austin,et al.  Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations , 2009, Biometrical journal. Biometrische Zeitschrift.

[28]  P Tugwell,et al.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. , 2008, Arthritis and rheumatism.

[29]  L. Smeeth,et al.  How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? , 2008, Arthritis and rheumatism.

[30]  V. Farewell,et al.  Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[31]  C. Patterson,et al.  Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging , 2007, Neurobiology of Aging.

[32]  L. Lue,et al.  Anti-inflammatory and Immune Therapy for Alzheimer's Disease: Current Status and Future Directions , 2007, Current neuropharmacology.

[33]  K. Hynynen,et al.  Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Staa,et al.  The General Practice Research Database: Now and the Future , 2007 .

[35]  Til Stürmer,et al.  Indications for propensity scores and review of their use in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.

[36]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[37]  J. Flammer,et al.  Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[38]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[39]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[40]  J. Hollowell,et al.  The General Practice Research Database: quality of morbidity data. , 1997, Population trends.

[41]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[42]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[43]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .